Targeting programmed cell death -1 (PD-1) and ligand (PD-L1): A new era in cancer active immunotherapy

Cites (230)

Items 201–224 of 224

1. A study of REOLYSIN in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP).
   Devalingam Mahalingam, Christos K Fountzilas, Jennifer L. Moseley, Nicole Noronha, Karol Cheetham, Adrian Dzugalo, Gerard James Nuovo, Andres A. Gutierrez, Sukeshi Patel Arora · 2017 · Journal of Clinical Oncology
2. Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial
   Marleen Kok, Hugo M. Horlings, Koen K Van de Vijver, T. Wiersma, Nicola S. Russell, Leonie Voorwerk, Karolina Sikorska, Erik D. van Werkhoven, Ingrid A.M. Mandjes, Inge Kemper et al. · 2017 · Annals of Oncology
3. Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
   Arnaud Scherpereel, Julien Mazières, Laurent Greillier, Pascal Dô, Olivier Bylicki, I. Monnet, R. Corre, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez, Olivier Molinier et al. · 2017 · Journal of Clinical Oncology
4. A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.
   Andrea Borghese Apolo, Amir Mortazavi, Mark N. Stein, Nicole N. Davarpanah, Rosa Maria Nadal, Howard L. Parnes, Yangmin M. Ning, Deneise C Francis, Lisa M. Cordes, Marilise Anne Berniger et al. · 2017 · Journal of Clinical Oncology
5. A randomized phase 2 study of the Bruton tyrosine kinase (Btk) inhibitor acalabrutinib alone or with pembrolizumab for metastatic pancreatic cancer (mPC).
   Michael James Overman, Charles D. Lopez, Al B. Benson, Sattva Swarup Neelapu, Niharika B. Mettu, Andrew H. Ko, Vincent M. Chung, John J. Nemunaitis, James Andrew Reeves, Johanna C. Bendell et al. · 2016 · Journal of Clinical Oncology
6. MA 19.01 A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)
   Yasushi Goto, M. Okada, Takashi Kijima, Kohei Aoe, Terufumi Kato, Nobukazu Fujimoto, Kazuhiko Nakagawa, Yuichiro Takeda, Toyoaki Hida, Kuninobu Kanai et al. · 2017 · Journal of Thoracic Oncology
7. First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma
   Yvonne Adeduni Efebera, Ashley Elizabeth Rosko, Craig C. Hofmeister, Joe Benner, Courtney E. Bakan, Kathleen Stamper, Tammy Lamb, Hollie Devine, Megan L. Sell, David Avigan et al. · 2015 · Blood
8. P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC
   Rudin, Charles, Cervantes, Andrés, Dowlati, Afshin, Besse, Benjamin, Ma, Brigette, Costa, Daniel, Schmid, Peter, Heist, Rebecca, Villaflor, Victoria, Sarkar, Indrani et al. · 2017 · Journal of Thoracic Oncology
9. Safety, PD-L1 expression, and clinical activity of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric or gastroesophageal junction cancer.
   Tomohiro Nishina, Kohei Shitara, Satoru Iwasa, Shuichi Hironaka, Kei Muro, Taito Esaki, Taroh Satoh, Kensei Yamaguchi, Nozomu Machida, Anja von Heydebreck et al. · 2016 · Journal of Clinical Oncology
10. Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Alex Francisco Herrera, Alison J. Moskowitz, Nancy L. Bartlett, Julie Marie Vose, Radhakrishnan Ramchandren, Tatyana A. Feldman, Ann Steward LaCasce, Stephen Maxted Ansell, Craig H. Moskowitz, Keenan Fenton et al. · 2017 · Blood
11. Cellular immunotherapies for prostate cancer
    Douglas G. McNeel · 2007 · Biomedicine & Pharmacotherapy
12. Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): long-lasting responses in the phase Ib KEYNOTE-012 study
    Rita Nanda, Jennifer M. Specht, E. Claire Dees, Ranaan Berger, S. Gupta, Ravit Geva, Lajos Pusztai, Kumudu Pathiraja, A. Ray, Vassiliki Karantza et al. · 2017 · European Journal of Cancer
13. Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.
    Jing Huang, Hongnan Mo, Dawei Wu, Xuelian Chen, Lanying Ma, Bo Lan, Qu Dong, Qing Yang, Binghe Xu · 2017 · Journal of Clinical Oncology
14. PD-1 blockade induces phosphorylated STAT3 and results in an increase of Tregs with reduced suppressive function
    David Michael Woods, Ruap Ramakrishnan, Andressa L. Sodré, Anders Berglund, Jeffrey S. Weber · 2017 · The Journal of Immunology
15. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced adrenocortical carcinoma from the JAVELIN solid tumor phase Ib trial: Safety and clinical activity.
    Christophe Le Tourneau, Christopher J. Hoimes, Corrine Zarwan, Deborah Jean Lee Wong, Sebastian Bauer, Martin Wermke, Rainer Claus, Kevin M. Chin, Anja von Heydebreck, Jean-Marie Cuillerot et al. · 2016 · Journal of Clinical Oncology
16. Preliminary results from subsets of patients (pts) with advanced gastric cancer (GC) and esophageal carcinoma (EC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
    Jayesh Desai, Michael Millward, Yee Chao, Hui Kong Gan, Mark Voskoboynik, Ben Markman, Amanda Rose Townsend, Victoria G. Atkinson, Andrew Xiuxuan Zhu, Juhee Song et al. · 2017 · Annals of Oncology
17. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated recurrent or refractory gastric cancer: Preliminary results from a phase I trial.
    Yoon‐Koo Kang, Toshihiko Doi, Shunsuke Kondo, Hyun-Choel Chung, Kei Muro, Christoph Helwig, Morihiro Watanabe, Yung‐Jue Bang · 2018 · Journal of Clinical Oncology
18. Preliminary results from a subset of patients (pts) with advanced head and neck squamous carcinoma (HNSCC) in a dose-escalation and dose-expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
    Lisa Glen Horvath, Jayesh Desai, Shahneen Kaur Sandhu, Anne E. O’Donnell, A.G. Hill, Sanjeev Deva, Ben Markman, Michael B. Jameson, Zegeng Chen, Xuemei Tan et al. · 2017 · Annals of Oncology
19. MA 19.02 Tremelimumab plus Durvalumab in First- or Second-Line Mesothelioma Patients: Final Analysis of the NIBIT-MESO-1 Study
    Luana Calabrò, A. Morra, Diana Giannarelli, Giovanni Amato, Erica Bertocci, Armida D’Incecco, Riccardo Danielli, Lucia Brilli, Franco Giannini, Maresa Altomonte et al. · 2017 · Journal of Thoracic Oncology
20. Recombinant humanized anti-PD-1 monoclonal antibody (JS001) as salvage treatment for advanced gastric adenocarcinoma: Preliminary results of an open-label, multi-cohort, phase Ib/II clinical study.
    Rui‐Hua Xu, Feng‐Hua Wang, Nong Xu, Lin Shen, Guanghai Dai, Xianglin Yuan, Jianhua Shi, Shujun Yang, J. Feng, Xichun Hu et al. · 2018 · Journal of Clinical Oncology
21. Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)
    Tarek M. Meniawy, Gary Edward Richardson, Amanda Rose Townsend, Jayesh Desai, Hui Kong Gan, Michael Leonard Friedlander, Lisa Glen Horvath, Michael B. Jameson, Shahneen Kaur Sandhu, Zhi‐Ying Wu et al. · 2017 · Annals of Oncology
22. The radiation oncology EMR as a quality and outcomes-based informatics platform: A multicenter pilot study.
    Jason Mark Pawlowski, Tammy Wotring, Andrew S. Kennedy · 2016 · Journal of Clinical Oncology
23. A phase I study of JS001, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with advanced solid tumors.
    Zhihong Chi, Bixia Tang, Xinan Sheng, Lu Si, Chuanliang Cui, Yan Kong, Dan Li, Si Ming Li, Xieqiao Yan, Li Mao et al. · 2017 · Journal of Clinical Oncology
24. Preliminary results from patients with urothelial carcinoma (UC) in a phase 1A/1B study of bgb-A317, an anti-PD-1 monoclonal antibody.
    Shahneen Kaur Sandhu, Andrew Graham Hill, Hui Kong Gan, Michael Leonard Friedlander, Mark Voskoboynik, Paula Barlow, Amanda Rose Townsend, James Song, Yun Zhang, Zhirong Shen et al. · 2018 · Journal of Clinical Oncology